N-arylrolipram derivatives as potent and selective PDE4 inhibitors
Derivatization of rolipram led to the identification of 3-[4-(3- cyclopentyloxy-4-methoxypbenyl)-2-oxo-pyrrolidin-1-yl]-5-(3- methoxybenzyloxy)-benzoic acid N',N'-dimethylhydrazide (4), a potent and selective inhibitor of PDE4, which inhibits the activation of human leukocytes with pIC50 values in the range of 7.3 - 7.8, and blocks antigen induced eosinophilia in Brown Norway rats at a dose of 1 mg/kg (i.t.).
Bacher, Edmond,Boer, Christiene,Bray-French, Katharine,Demnitz, F. W. Joachim,Keller, Thomas H.,Mazzoni, Lazzaro,Mueller, Thomas,Walker, Christoph
Synthesis and structure - Activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes
Structure activity studies of N-phenylrolipram derivatives have led to the identification of highly potent PDE4 inhibitors. The potential of these inhibitors for cellular activity was routinely assessed in an assay of fMLP induced oxidative burst in human eosinophils. Since first generation PDE4 inhibitors have been plagued with a number of unwanted side effects, parallel structure activity studies for competition with the [3H]-rolipram binding site in rat brain were performed. In this fashion 5-[4-(3-cyclopentyloxy-4-methoxyphenyl) -2-oxo-pyrrolidin-1-y1]-3-(3-methoxybenzyloxy)benzoic acid N′,N′-dimethylhydrazide (22) was identified as a potent inhibitor of PDE4 which exhibits >1000 fold selectivity versus PDE3, and is a nanomolar inhibitor in all the cellular assays tested. Studies on the stereoselectivity of PDE4 inhibition of this class of rolipram based compounds revealed, that for example (S)-11 is a more potent inhibitor than (R)-11. This effect can also be observed in primary human cells where the (S)-enantiomer is about 10 fold more potent than the corresponding (R)-enantiomer.
Keller, Thomas H.,Bray-French, Katharine,Demnitz, F. W. Joachim,Mueller, Thomas,Pombo-Villar, Esteban,Walker, Christoph
p. 1009 - 1017
(2007/10/03)
Synthesis of N-arylrolipram derivatives - Potent and selective phosphodiesterase-IV inhibitors - by copper catalyzed lactam-aryl halide coupling
The copper catalysed coupling of rolipram (1) with a wide variety of aryl halides (2) affords N-arylrolipram derivatives (3), potent and selective phosphodiesterase type-IV inhibitors.
Aebischcr, Esther,Bacher, Edmond,Joachim Demnitz,Keller, Thomas H.,Kurzmeyer, Miriam,Ortiz, Marta L.,Pombo-Villar, Esteban,Weber, Hans-Peter
p. 2225 - 2229
(2007/10/03)
More Articles about upstream products of 220284-70-8